Nabiximols (USAN, trade name Sativex) is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom despite a lack of convincing evidence of effectiveness for spasticity reduction (see below). Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. The drug is a pharmaceutical product standardized in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD).